{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:26Z","timestamp":1787020106684,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Suqian Sci&Tech Program","award":["KY202311"],"award-info":[{"award-number":["KY202311"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04295-y","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:45:11Z","timestamp":1759491911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TPD52 promotes the proliferation and metastasis of gastric cancer cells"],"prefix":"10.1186","volume":"25","author":[{"given":"Shunhao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinliang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"4295_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"4295_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4295_CR3","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4295_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis PD, Ishii KJ, Schliehe C. Challenges in developing personalized neoantigen cancer vaccines. Nat Rev Immunol. 2024;24:213\u201327.","journal-title":"Nat Rev Immunol"},{"key":"4295_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.01.008","author":"NP Tjader","year":"2024","unstructured":"Tjader NP, Toland AE. Immunotherapy for colorectal cancer: insight from inherited genetics. Trends Cancer. 2024. https:\/\/doi.org\/10.1016\/j.trecan.2024.01.008.","journal-title":"Trends Cancer"},{"key":"4295_CR6","volume":"1879","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yan Q, Zeng Z, Fan C, Xiong W. Advances and prospects of mRNA vaccines in cancer immunotherapy. Biochimica et Biophysica Acta (BBA). 2024;1879:189068.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"4295_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100878","volume":"4","author":"MA Huseni","year":"2023","unstructured":"Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, et al. CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023;4:100878.","journal-title":"Cell Rep Med"},{"key":"4295_CR8","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652\u201369.","journal-title":"Cell"},{"key":"4295_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01930-8","volume":"23","author":"DX Wang","year":"2024","unstructured":"Wang DX, Long JY, Li RZ, Zhang DL, Liu H, Liu J, et al. Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments. Mol Cancer. 2024;23:15.","journal-title":"Mol Cancer"},{"key":"4295_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/CAD.0000000000001557","volume":"35","author":"X Wang","year":"2024","unstructured":"Wang X, Yang K, Yang Y, Wang X, Yuan K. Immunotherapy rechallenge of advanced lung adenocarcinoma with cadonilimab (PD-1\/CTLA-4 bi-specific antibody): a case report. Anticancer Drugs. 2024;35:288\u201391.","journal-title":"Anticancer Drugs"},{"key":"4295_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/CAD.0000000000001498","volume":"35","author":"E Eylemer Mocan","year":"2024","unstructured":"Eylemer Mocan E, Yeked\u00fcz E, Karata\u015f G, Yazgan SC, K\u00f6ksoy EB, \u00c7ay \u015eenler F, Utkan G, Demirkazik A, Akbulut H, \u00dcr\u00fcn Y. Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients. Anticancer Drugs. 2024;35:190\u20134.","journal-title":"Anticancer Drugs"},{"key":"4295_CR12","doi-asserted-by":"publisher","first-page":"e001895","DOI":"10.1136\/jitc-2020-001895","volume":"9","author":"C Liu","year":"2021","unstructured":"Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, Zhang C, Fang L, Guan X, Shi J, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9:e001895.","journal-title":"J Immunother Cancer"},{"key":"4295_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004414","author":"X Wang","year":"2022","unstructured":"Wang X, Zhou T, Chen X, Wang Y, Ding Y, Tu H, et al. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004414.","journal-title":"J Immunother Cancer"},{"key":"4295_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001652","author":"F Cosso","year":"2024","unstructured":"Cosso F, Lavacchi D, Messerini L, Briganti V, Castiglione F, Brugia M, et al. Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma. Anticancer Drugs. 2024. https:\/\/doi.org\/10.1097\/CAD.0000000000001652.","journal-title":"Anticancer Drugs"},{"key":"4295_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ymthe.2022.09.001","volume":"31","author":"Q Wu","year":"2023","unstructured":"Wu Q, Yue X, Liu H, Zhu Y, Ke H, Yang X, et al. Map7d2 reduces CD8(+) cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer. Mol Ther. 2023;31:90\u2013104.","journal-title":"Mol Ther"},{"key":"4295_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","volume":"625","author":"A Cui","year":"2024","unstructured":"Cui A, Huang T, Li S, Ma A, P\u00e9rez JL, Sander C, et al. Dictionary of immune responses to cytokines at single-cell resolution. Nature. 2024;625:377\u201384.","journal-title":"Nature"},{"key":"4295_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626:727\u201336.","journal-title":"Nature"},{"key":"4295_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/jcb.29869","volume":"122","author":"JW Kang","year":"2021","unstructured":"Kang JW, Kim Y, Lee Y, Myung K, Kim YH, Oh CK. AML poor prognosis factor, TPD52, is associated with the maintenance of haematopoietic stem cells through regulation of cell proliferation. J Cell Biochem. 2021;122:403\u201312.","journal-title":"J Cell Biochem"},{"key":"4295_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/mc.22038","volume":"53","author":"N Roslan","year":"2014","unstructured":"Roslan N, Bi\u00e8che I, Bright RK, Lidereau R, Chen Y, Byrne JA. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinog. 2014;53:807\u201319.","journal-title":"Mol Carcinog"},{"key":"4295_CR20","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1038\/s41418-023-01186-1","volume":"30","author":"X Jiang","year":"2023","unstructured":"Jiang X, Peng J, Xie Y, Xu Y, Liu Q, Cheng C, et al. Oxoglutarate dehydrogenase-like inhibits the progression of hepatocellular carcinoma by inducing DNA damage through non-canonical function. Cell Death Differ. 2023;30:1931\u201342.","journal-title":"Cell Death Differ"},{"key":"4295_CR21","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1080\/15548627.2021.1917130","volume":"17","author":"Y Fan","year":"2021","unstructured":"Fan Y, Hou T, Gao Y, Dan W, Liu T, Liu B, et al. Acetylation-dependent regulation of TPD52 isoform 1 modulates chaperone-mediated autophagy in prostate cancer. Autophagy. 2021;17:4386\u2013400.","journal-title":"Autophagy"},{"key":"4295_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2108656","volume":"18","author":"CR Elizondo","year":"2022","unstructured":"Elizondo CR, Bright JD, Bright RK. Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8\u2009+\u2009T cells with a regulatory phenotype. Hum Vaccin Immunother. 2022;18:2108656.","journal-title":"Hum Vaccin Immunother"},{"key":"4295_CR23","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/21645515.2019.1689746","volume":"16","author":"CR Elizondo","year":"2020","unstructured":"Elizondo CR, Bright JD, Byrne JA, Bright RK. Analysis of the CD8\u2009+\u2009IL-10\u2009+\u2009T cell response elicited by vaccination with the oncogenic tumor-self protein D52. Hum Vaccin Immunother. 2020;16:1413\u201323.","journal-title":"Hum Vaccin Immunother"},{"key":"4295_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ccell.2018.03.010","volume":"33","author":"Y Liu","year":"2018","unstructured":"Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, et al. Comparative molecular analysis of Gastrointestinal adenocarcinomas. Cancer Cell. 2018;33:721\u2013e735728.","journal-title":"Cancer Cell"},{"key":"4295_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.799278","volume":"9","author":"T Yue","year":"2021","unstructured":"Yue T, Liu X, Zuo S, Zhu J, Li J, Liu Y, et al. BCL2A1 and CCL18 are predictive biomarkers of cisplatin chemotherapy and immunotherapy in colon cancer patients. Front Cell Dev Biol. 2021;9:799278.","journal-title":"Front Cell Dev Biol"},{"key":"4295_CR26","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3892\/mmr.2020.11250","volume":"22","author":"X Shen","year":"2020","unstructured":"Shen X, Wu S, Zhang J, Li M, Xu F, Wang A, et al. Wild\u2013type IDH1 affects cell migration by modulating the PI3K\/AKT\/mTOR pathway in primary glioblastoma cells. Mol Med Rep. 2020;22:1949\u201357.","journal-title":"Mol Med Rep"},{"key":"4295_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713175","author":"B Huang","year":"2023","unstructured":"Huang B, Chen Q, Ye Z, Zeng L, Huang C, Xie Y, et al. Construction of a matrix cancer-associated fibroblast signature gene-based risk prognostic signature for directing immunotherapy in patients with breast cancer using single-cell analysis and machine learning. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241713175.","journal-title":"Int J Mol Sci"},{"key":"4295_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42060-x","volume":"13","author":"QT Dong","year":"2023","unstructured":"Dong QT, Ma DD, Gong Q, Lin ZY, Li ZH, Ye JX, et al. FAM3 family genes are associated with prognostic value of human cancer: a pan-cancer analysis. Sci Rep. 2023;13:15144.","journal-title":"Sci Rep"},{"key":"4295_CR29","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.stem.2021.04.011","volume":"28","author":"C Wang","year":"2021","unstructured":"Wang C, Li Y, Jia L, Kim JK, Li J, Deng P, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021;28:1597-e16131597.","journal-title":"Cell Stem Cell"},{"key":"4295_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s43018-022-00344-7","volume":"3","author":"Z Feng","year":"2022","unstructured":"Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, et al. Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nat Cancer. 2022;3:581\u201394.","journal-title":"Nat Cancer"},{"key":"4295_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imr.12978","volume":"302","author":"R Mhaidly","year":"2021","unstructured":"Mhaidly R, Mechta-Grigoriou F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol Rev. 2021;302:259\u201372.","journal-title":"Immunol Rev"},{"key":"4295_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02935-3","volume":"43","author":"W Luo","year":"2024","unstructured":"Luo W, Wen T, Qu X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. J Exp Clin Cancer Res. 2024;43:8.","journal-title":"J Exp Clin Cancer Res"},{"key":"4295_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00523-y","volume":"8","author":"Y Hu","year":"2024","unstructured":"Hu Y, Recouvreux MS, Haro M, Taylan E, Taylor-Harding B, Walts AE, et al. INHBA(+) cancer-associated fibroblasts generate an immunosuppressive tumor microenvironment in ovarian cancer. NPJ Precis Oncol. 2024;8:35.","journal-title":"NPJ Precis Oncol"},{"key":"4295_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1307588","volume":"14","author":"C Li","year":"2023","unstructured":"Li C, Yang L, Zhang Y, Hou Q, Wang S, Lu S, et al. Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer. Front Immunol. 2023;14:1307588.","journal-title":"Front Immunol"},{"key":"4295_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1210910","volume":"13","author":"H Wang","year":"2023","unstructured":"Wang H, Liu Z, Du Y, Cheng X, Gao S, Gao Y, et al. TPD52L2 as a potential prognostic and immunotherapy biomarker in clear cell renal cell carcinoma. Front Oncol. 2023;13:1210910.","journal-title":"Front Oncol"},{"key":"4295_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634617","volume":"11","author":"W Ye","year":"2021","unstructured":"Ye W, Luo C, Liu F, Liu Z, Chen F. CD96 correlates with immune infiltration and impacts patient prognosis: a pan-cancer analysis. Front Oncol. 2021;11:634617.","journal-title":"Front Oncol"},{"issue":"2","key":"4295_CR37","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.18632\/aging.205447","volume":"16","author":"SW Lai","year":"2024","unstructured":"Lai SW, Cheng YC, Kiu KT, Yen MH, Chen YW, Yadav VK, et al. PROX1 interaction with \u03b1-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance. Aging. 2024;16(2):1620\u201339.","journal-title":"Aging"},{"key":"4295_CR38","doi-asserted-by":"publisher","first-page":"e2305653","DOI":"10.1002\/advs.202305653","volume":"11","author":"Q Yan","year":"2024","unstructured":"Yan Q, Fang X, Liu X, Guo S, Chen S, Luo M, Lan P, Guan XY. Loss of ESRP2 activates TAK1-MAPK signaling through the fetal RNA-Splicing program to promote hepatocellular carcinoma progression. Adv Sci (Weinh). 2024;11:e2305653.","journal-title":"Adv Sci (Weinh)"},{"key":"4295_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41401-023-01165-9","volume":"45","author":"JX Xiong","year":"2024","unstructured":"Xiong JX, Li YT, Tan XY, Chen T, Liu BH, Fu L. Targeting PRSS23 with Tipranavir induces gastric cancer stem cell apoptosis and inhibits growth of gastric cancer via the MKK3\/p38 MAPK-IL24 pathway. Acta Pharmacol Sin. 2024;45:405\u201321.","journal-title":"Acta Pharmacol Sin"},{"key":"4295_CR40","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, Neeser A, Pires IS, Yousefpour P, Gregory J, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148\u2013e31653120.","journal-title":"Cell"},{"key":"4295_CR41","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2159-8290.CD-23-0559","volume":"14","author":"A Das","year":"2024","unstructured":"Das A, Fernandez NR, Levine A, Bianchi V, Stengs LK, Chung J, et al. Combined immunotherapy improves outcome for Replication-Repair-Deficient (RRD) high-grade glioma failing anti-PD-1 monotherapy: a report from the international RRD consortium. Cancer Discov. 2024;14:258\u201373.","journal-title":"Cancer Discov"},{"key":"4295_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3851-y","volume":"17","author":"GD Cao","year":"2017","unstructured":"Cao GD, Chen K, Chen B, Xiong MM. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. BMC Cancer. 2017;17:841.","journal-title":"BMC Cancer"},{"key":"4295_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161219","volume":"11","author":"GD Cao","year":"2016","unstructured":"Cao GD, Chen K, Xiong MM, Chen B. HER3, but not HER4, plays an essential role in the clinicopathology and prognosis of gastric cancer: a meta-analysis. PLoS ONE. 2016;11:e0161219.","journal-title":"PLoS ONE"},{"key":"4295_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100936","volume":"68","author":"X Qu","year":"2023","unstructured":"Qu X, Liu B, Wang L, Liu L, Zhao W, Liu C, et al. Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer. Drug Resist Updat. 2023;68:100936.","journal-title":"Drug Resist Updat"},{"key":"4295_CR45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","volume":"187","author":"Y Shapir Itai","year":"2024","unstructured":"Shapir Itai Y, Barboy O, Salomon R, Bercovich A, Xie K, Winter E, Shami T, Porat Z, Erez N, Tanay A, et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell. 2024;187:375\u2013e389318.","journal-title":"Cell"},{"key":"4295_CR46","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.23.00580","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, Chowdhury A, Li YY, Wang X, Spurr L, et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 Blockade in Non-Small-Cell lung cancer. J Clin Oncol. 2024;42:1311. https:\/\/doi.org\/10.1200\/JCO.23.00580.","journal-title":"J Clin Oncol"},{"key":"4295_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/1078-0432.CCR-23-2213","volume":"30","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Qin G, Bai F, Wu X, Ke H, et al. Biomarkers of pathologic complete response to neoadjuvant immunotherapy in mismatch Repair-Deficient colorectal cancer. Clin Cancer Res. 2024;30:368\u201378.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04295-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:45:12Z","timestamp":1759491912000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04295-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4295"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04295-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the principles outlined in the Declaration of Helsinki. The protocol of this study was approved by the institutional ethics commission of the Affiliated Suqian First People\u2019s Hospital of Nanjing Medical University, and all participants wrote informed consent (2024-SL-0063).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"690"}}